Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;19(4):663-669.
doi: 10.1111/pedi.12635. Epub 2018 Mar 4.

Successful off-label sulfonylurea treatment of neonatal diabetes mellitus due to chromosome 6 abnormalities

Laure Garcin  1 , Dulanjalee Kariyawasam  1   2   3 , Kanetee Busiah  1 , Anne-Laure Fauret-Amsellem  4 , Fleur Le Bourgeois  5 , Laurence Vaivre-Douret  2   6   7   8 , Hélène Cavé  4   9 , Michel Polak  1   2   3   10 , Jacques Beltrand  1   2   3   10
Affiliations
Review

Successful off-label sulfonylurea treatment of neonatal diabetes mellitus due to chromosome 6 abnormalities

Laure Garcin et al. Pediatr Diabetes. 2018 Jun.

Abstract

Chromosome 6 abnormalities such as paternal uniparental isodisomy, paternal 6q24 duplication, and maternal DMR (differentially methylated region) hypomethylation are a common cause of transient neonatal diabetes mellitus (TNDM). Oral sulfonylurea (SU) is used off-label to treat permanent neonatal diabetes mellitus owing to potassium channel mutation but has not been evaluated in TNDM. Our objective was to evaluate the efficacy and safety of SU therapy in chromosome 6-related TNDM. Description of 3 case reports and literature review was the subject of the study. SU therapy was successful in 2 patients (initiated during neonatal life in 1 patient and during relapse in the other) but failed in the other despite the use of high dosage. The literature review identified 11 cases of patients with chromosome 6-related TNDM treated with SU, including 4 treated before remission and 7 after the relapse. SU therapy was consistently effective, although 4 patients treated after the relapse required multiple oral medications. None of the patients needed associated insulin therapy. No side effects of SU or complications of diabetes were reported. SU seems effective and safe in chromosome 6-related TNDM treatment when used to treat the initial episode of diabetes or the relapse. It improves patients' and families' quality of life. SU is available only as oral tablets. A pediatric dosage form would facilitate the treatment of neonates and infants.

Keywords: chromosome 6; monogenic diabetes; sulfonylureas; transient neonatal diabetes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Supplementary concepts

LinkOut - more resources